The results of the study reveal HDAC5 as a novel inflammatory mediator in RA and indicate that methods for restoring HDAC5 expression in vivo or the creation of HDAC inhibitors that do not interfere with HDAC5 function, may prove beneficial in the treatment of RA (Angiolilli et al. 2014). This evidence concerns the gene HDAC9 and rheumatoid arthritis.